HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of...

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• High-risk non-muscle invasive bladder cancer (HR-NMIBC) presents unpredictable clinical outcomes.
• Current risk stratification tools inadequately guide treatment, leading to undertreatment or overtreatment.
• DNA methylation is a promising biomarker in various cancers, but its role in HR-NMIBC requires further investigation.

Purpose of the Study:

• To identify novel DNA methylation markers for predicting clinical outcomes in HR-NMIBC.
• To assess the potential of genome-wide DNA methylation analysis for guiding patient management.
• To discover epigenetic markers that predict tumor behavior at initial diagnosis.

Main Methods:

• Genome-wide DNA methylation analysis using Illumina HumanMethylation450 BeadChip arrays on 21 primary HR-NMIBC tumors.
• Validation of identified CpG loci using bisulfite Pyrosequencing on the initial cohort and an independent cohort of 32 HR-NMIBC tumors.
• Correlation of methylation patterns with 1-year recurrence and progression outcomes.

Main Results:

• Genome-wide analysis identified 206 CpG loci differentiating non-recurrent from aggressive HR-NMIBC tumors.
• A combination of hypermethylation at cg11850659 and hypomethylation at cg01149192 predicted recurrence/progression within 1 year.
• This combined methylation signature demonstrated 83% sensitivity and 79% specificity for predicting adverse outcomes.

Conclusions:

• This study presents the first genome-wide DNA methylation analysis in a HR-NMIBC cohort with known 1-year outcomes.
• Novel epigenetic markers were identified that show potential for predicting clinical behavior in HR-NMIBC.
• These findings may assist in tailoring patient management strategies for this challenging disease.